Notice for tezacaftor/ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)

For the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regualtor (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence